Continuous Glucose Monitoring (CGM) Technology

Continuous glucose monitoring represents a fundamental shift in how glucose levels are tracked in people with diabetes, replacing periodic finger-stick readings with real-time, near-continuous data streams. This page covers the technical structure of CGM devices, how they function at the physiological level, the clinical situations in which they are deployed, and the criteria that guide device selection. Understanding CGM technology is relevant to the broader landscape of diabetes technology and to anyone seeking orientation to endocrinology as a field.

Definition and scope

A continuous glucose monitor is a wearable medical device that measures glucose concentrations in interstitial fluid at regular intervals — typically every 1 to 15 minutes — and transmits that data to a display device or smartphone. The U.S. Food and Drug Administration (FDA) classifies CGM systems as Class II or Class III medical devices under 21 CFR Part 880, depending on their intended use and whether they are approved for non-adjunctive (treatment-decision) use without a confirmatory finger-stick.

CGM systems fall into two broad regulatory and functional categories:

• Real-Time CGM (rtCGM): Continuously transmits glucose readings and trend arrows to the receiver or app. Examples cleared by the FDA include the Dexcom G7 and the Abbott FreeStyle Libre 3.
• Intermittently Scanned CGM (isCGM): Requires the user to wave a reader over the sensor to retrieve a reading, rather than transmitting automatically. Abbott's FreeStyle Libre 2 was the defining product in this category before the Libre 3 transition.

The FDA's Center for Devices and Radiological Health (CDRH) maintains a product classification database where cleared CGM devices are listed. Non-adjunctive clearance — meaning the device's readings alone can guide insulin dosing — was a significant regulatory milestone first achieved in the United States in 2016 with the Dexcom G5.

How it works

CGM sensors use an electrochemical detection method. A small, flexible filament — typically 5 to 8 millimeters in length — is inserted subcutaneously into the interstitial tissue of the abdomen, upper arm, or back of the upper arm. The filament is coated with glucose oxidase, an enzyme that reacts with glucose molecules in interstitial fluid to generate a small electrical current. A transmitter attached to the skin reads that current and converts it to a glucose value in milligrams per deciliter (mg/dL) or millimoles per liter (mmol/L).

Because interstitial glucose lags behind blood glucose by approximately 5 to 10 minutes under dynamic conditions — such as rapidly rising or falling glucose after a meal or insulin dose — CGM systems apply calibration algorithms to minimize physiologic lag and improve accuracy. The accuracy benchmark used by the FDA and device manufacturers is Mean Absolute Relative Difference (MARD): lower MARD values indicate higher accuracy. The Abbott FreeStyle Libre 3 has published a MARD of 7.9% in clinical validation data submitted to the FDA.

Trend arrows displayed alongside glucose values indicate the rate and direction of change, providing information that a single static reading cannot convey. A reading of 110 mg/dL with a rapidly falling arrow carries different clinical implications than the same reading with a stable arrow.

Sensor wear duration varies by product: the Dexcom G7 sensor is approved for 10 days, while the Abbott FreeStyle Libre 3 is approved for 14 days. Sensors are single-use and must be replaced at the end of their approved wear period.

Common scenarios

CGM is deployed across a range of clinical contexts, each with distinct glucose management goals defined by professional society guidance. The American Diabetes Association (ADA) Standards of Care in Diabetes (published annually in the journal Diabetes Care) includes evidence-graded recommendations for CGM use.

Type 1 diabetes: CGM is considered standard of care for adults and children with Type 1 diabetes on intensive insulin regimens. The landmark DIAMOND and GOLD randomized controlled trials demonstrated statistically significant reductions in hemoglobin A1c among adults with Type 1 diabetes using rtCGM compared to self-monitoring of blood glucose alone.

Type 2 diabetes on insulin: The ADA's 2023 Standards of Care extended a Level A recommendation (highest evidence grade) for rtCGM use to adults with Type 2 diabetes using multiple daily injections of insulin.

Type 2 diabetes not on insulin: Evidence supports CGM as a behavioral feedback tool in this population, though the evidence grade is lower. The 2023 ADA Standards of Care assigned a Level B recommendation for this use.

Integration with insulin pump systems: CGM is a required component of automated insulin delivery (AID) systems, sometimes called closed-loop or hybrid closed-loop systems. These systems link CGM readings to an insulin pump algorithm that adjusts basal insulin delivery automatically. This integration is covered in detail on the insulin pump and closed-loop systems page.

Pregnancy: CGM use in pregnant individuals with Type 1 diabetes has demonstrated improved neonatal outcomes in the CONCEPTT trial, a multicenter randomized controlled trial published in The Lancet in 2017.

Decision boundaries

Selecting a specific CGM system involves evaluation across four dimensions:

1. Regulatory approval status: Whether the device holds non-adjunctive clearance from the FDA CDRH, which determines whether insulin doses can be adjusted based on CGM readings alone.
2. Integration compatibility: Whether the CGM is compatible with a specific insulin pump or AID algorithm. Not all CGM-pump pairings are FDA-approved as integrated systems.
3. Wear duration and insertion burden: Sensor lifespan ranges from 7 to 14 days across currently cleared devices, affecting replacement frequency and cost.
4. Alarm and alert configuration: rtCGM systems offer programmable high and low glucose alarms; isCGM systems typically offer only optional low-glucose alarms. For patients at high risk of severe hypoglycemia, alarm capability may drive device selection.

Insurance coverage criteria — governed by Medicare's Local Coverage Determination (LCD) L33822 and commercial payer policies — also define access boundaries. Medicare CGM coverage, administered through the Centers for Medicare & Medicaid Services (CMS), requires documentation of a diabetes diagnosis and therapeutic insulin use, with specific documentation requirements outlined in LCD L33822.

The regulatory framework governing these determinations is part of the broader compliance environment described on the regulatory context for endocrinology page.

Glucose targets that CGM data are measured against — including Time in Range (TIR), defined as the percentage of readings between 70 and 180 mg/dL — are standardized in the international consensus report published in Diabetes Care in 2019, authored under the International Consensus on Time in Range working group.

References

• U.S. Food and Drug Administration — Center for Devices and Radiological Health (CDRH), 21 CFR Part 880
• American Diabetes Association — Standards of Care in Diabetes (Diabetes Care, annual)
• Centers for Medicare & Medicaid Services — Local Coverage Determination L33822 (Continuous Glucose Monitors)
• FDA 510(k) and De Novo Product Classification Database — CGM Devices
• International Consensus on Time in Range — Diabetes Care, 2019
• CONCEPTT Trial — The Lancet, 2017 (Continuous Glucose Monitoring in Pregnant Women with Type 1 Diabetes)

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)